Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securi
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
11:00pm, Thursday, 09'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
NEW ORLEANS, LA / ACCESSWIRE / January 9, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until Febru
KYTX LAWSUIT ALERT: Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
04:30pm, Thursday, 09'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) pursuant and/or tra
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
09:30am, Thursday, 09'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics Inc
09:15am, Thursday, 09'th Jan 2025
LOS ANGELES, CA / ACCESSWIRE / January 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, I
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - KYTX
07:25am, Thursday, 09'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna T
NEW YORK , Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX during th
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
NEW ORLEANS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 7, 2025 to file lead plaintiff applications in a sec
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
05:30pm, Wednesday, 08'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securiti
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit – KYTX
12:49pm, Wednesday, 08'th Jan 2025
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action secu
